Category: patients

  • Should we be worried about Omicron ‘stealth variant’ BA.2?

    With healthcare systems around the world labouring under the strain of dealing with the Omicron wave of COVID-19 infections, attention is already turning to a new sub-variant that is starting to emerge in some countries, including the UK, India and Denmark. Dubbed BA.2, the sub-variant of Omicron (BA.1) hasn’t been classed as a variant of […]

  • Chronic kidney disease: treating a silent killer

    In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. pharmaphorum caught up with AZ’s Joris Silon to discuss unmet needs in the condition. “Many times, I have talked to nephrologists who take care of patients with chronic kidney disease in the later stages, […]

  • NICE expands cover for AZ’s high potassium drug Lokelma

    NICE has recommended extending funding via the NHS for AstraZeneca’s elevated potassium therapy Lokelma in new guidance, making it easier to receive the drug outside hospital settings. The new guidance means adults living with persistently high potassium levels in the blood – a condition known as hyperkalaemia – can now get repeat prescriptions for Lokelma […]

  • The evolution of clinical trials: the pharmaphorum podcast

    In the latest episode of the pharmaphorum podcast, Dr Paul Tunnah speaks to head of Patient Engagement at Syneos Health, Marie Emms, and Elligo executive vice president and general manager of Worldwide Clinical Trials Early Phase Services, Keith Fern. Together they discuss the changing nature of clinical trials how COVID-19 impacted the sector, and the […]

  • EMA sets out proposals to reform EU’s clinical trials framework

    The European Commission, EMA and national regulators within the EU have launched an initiative to change the way clinical trials are designed and run in order to position the bloc as an international “focal point” for clinical research. The broad strokes of the proposals are laid out in a document entitled Accelerating Clinical Trials in […]

  • How to innovate and influence people in times of misinformation

    Rewind to late 2019. If you had been told that within a few months, you’d be living in the middle of the biggest pandemic since the 1918 global flu outbreak, but that thanks to new mRNA technology, vaccine prototypes would be ready for trials within weeks and the first shots would go into arms before […]

  • Pfizer, Moderna are prepping new vaccines for Omicron

    With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of their mRNA-based shots that are tailored to the new variant. Pfizer has said that a COVID-19 jab specifically targeting Omicron, as well as other existing variants, […]

  • What HCPs think about mandatory vaccination

    What HCPs think about mandatory vaccination The practice of making vaccinations mandatory within a population has always been controversial. Historically, the first example of this was during the smallpox epidemic in the 1800s, when some European countries attempted to make vaccination against the disease compulsory. While it is hard to argue against the overall aim […]

  • Putting patient perspectives at the heart of kidney cancer research

    Kidney cancer is the 14th most common cancer, with approximately 400,000 new cases worldwide every year. Renal cell carcinoma (RCC) is by far the most prevalent type of cancer originating from the kidney, making up nine out of ten kidney cancer diagnoses. As chief medical officer, head of global medical affairs, patient safety and patient […]

  • Digital health innovation in 2022: Anticipating healthcare trends ahead of the J.P. Morgan week

    We spoke with Tanja Dowe, ahead of the annual  J.P. Morgan Health Care Conference 2022, about radical innovation in healthcare, including the potential of digital solutions to diagnose disease earlier, using digital therapeutics or preventive digital solutions more efficiently, and making use of technologies that result in accelerated drug discovery and development. “J.P. Morgan week […]

  • Nine for 2022: International issues that are compelling, new or changed in 2022

    The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. Despite an estimated 9.25 billion doses administered globally by 4th January, with 25 different vaccines either approved for use or under emergency use authorisation, 2022 […]

  • FDA clears Pfizer, BioNTech COVID booster for younger teens

    The FDA has authorised the first COVID-19 booster vaccine for teenagers in the 12 to 15 age group, giving the okay for wider use of Pfizer and BioNTech’s Comirnaty shot as it tries to keep the Omicron variant under control. The US regulator has also reduced the time between completion of the first two doses […]

  • Theranos founder Elizabeth Holmes guilty of fraud, says jury

    Elizabeth Holmes, the founder and former chief executive of the blood testing startup Theranos, has been convicted of defrauding investors by a jury in a California court and is facing a prison sentence. Prosecutors claimed that Holmes (37) knowingly misled shareholders in Theranos with the promise that the company’s technology could diagnose a battery of […]

  • Insights from the WHO’s Global Strategy on Digital Health event

    The World Health Organization (WHO) recently held a virtual panel discussion during Digital Health Week with speakers from around the world to talk about global strategy on digital health and collective opportunities for catalysing collaborative action. The panel focused on the objectives of the WHO’s Global Strategy on Digital Health 2020-2025, which aims to develop […]

  • UK study finds Omicron cases less likely to be hospitalised

    People infected with the Omicron variant of COVID-19 are 50% to 70% less likely to be admitted to hospital than those infected with other variants, according to a UK study. The new analysis from the UK Health Security Agency (UKHSA) also says Omicron infections are estimated to be between 31% to 45% less likely to […]

  • The Considered pharmaceutical marketing experiment

    COVID-19 has changed everything – at least that’s David Hunt’s plan for pharmaceutical marketing. The former CEO of Havas Lynx recently launched a new agency in the US called The Considered, with the intent to break the traditional pharma marketing rules and shake up the industry. “There is some brilliant work that takes place by […]

  • 2021 in review: Building the framework of a patient-centric industry

    Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action. However, we have seen a framework of guidelines and recommendations during the last year on everything from increasing diversity to producing lay summaries, start to take shape. As part of […]

  • Pfizer pauses Duchenne gene therapy trial after patient death

    Pfizer has called a halt to a clinical trial of its gene therapy for Duchenne muscular dystrophy as it investigates the unexpected death of a young male patient. In an update posted today the pharma giant said “we do not yet have complete information and are actively working with the trial site investigator to understand […]

  • Patient engagement processes: the pharmaphorum podcast

    This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led by clinician, consultant and patient advocate, Mark Duman. Joining him to discuss the importance of patient engagement are Johnson & Johnson’s global patient engagement leader Katherine Capperella, Novartis’ head of patient engagement Mark Boutin, and […]

  • CDC eyes safety of J&J COVID jab as EU backs booster

    Johnson & Johnson’s also-ran COVID-19 vaccine has been cleared in the EU as a booster shot, although its role in the US could be impacted by new data on rare blood clots. A Centres for Disease and Control Prevention (CDC) advisory committee is scheduled to meet today to discuss the new results, according to a […]

  • From patient engagement to patient centricity

    Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon. But the difference between them is not like the choice between “agreeing” and “aligning” or “getting together later” and “taking this offline.” Going from the vital activity of patient engagement to the more encompassing state of […]

  • Patients ‘29% less likely to be hospitalised with Omicron’

    Data from a real-world study South Africa has indicated that the Omicron variant of COVID-19 is 29% less likely to cause hospitalisation among infected adults than other strains – although the researchers behind the work stress the findings are preliminary. The results – released by healthcare insurance group Discovery SA and the South African Medical […]

  • Booster COVID jabs offered to all adults in England

    The UK government has said it will step up its COVID-19 booster vaccination dramatically, with everyone in England aged over 18 offered a third dose before the end of the month. Westminster has promised additional support for the devolved administrations in Scotland, Wales and Northern Ireland to step up the booster campaign, and Scotland has […]

  • Omicron may evade Pfizer/BioNTech COVID jab, says study

    Preliminary study results from South Africa have suggested that antibodies stimulated by Pfizer and BioNTech’s Comirnaty are less effective against the new COVID-19 variant Omicron. A study by the African Health Research Institute (AHRI) has found that the less of immune protection was “extensive but incomplete,” meaning that some level of immunity was retained against […]

  • Omicron set to dominate in UK within weeks, says expert

    The Omicron variant could supersede other strains of COVID-19 within the next few weeks to become dominant in the UK, according to an infectious diseases expert. Professor Paul Hunter of the University of East Anglia told the BBC this morning that it is likely there is already more than 1,000 cases of Omicron (also known […]

  • Social Health: What it is and why it matters for pharma

    Health Union surveyed 2,371 patients across a diverse representation of health conditions to better understand how social health can positively impact patient experiences. The survey found that: 95% of patients use online social resources for health reasons Three out of four patients use online social resources at critical inflection points in their health journey Through social […]

  • The booming life sciences sector needs dynamic real estate support

    Bruntwood SciTech is the UK’s leading property provider dedicated to driving the growth of the science and technology sector. UK life sciences are buoyant with the success of the COVID-19 vaccine programme and a stream of innovation and investment marking it out for a starring role in the UK’s economic future. The government has pledged […]

  • How biomarkers and bioanalytics are changing R&D

    Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new gold standard for clinical research. Thomas Turi, chief scientific officer at Nexelis, tells us how a biomarker-led R&D approach is transforming drug development in disease areas like non-alcoholic steatohepatitis (NASH) […]

  • Health Innovators: Senseonics’ Francine Kaufman

    In the most recent of the Health Innovators video series, pharmaphorum’s founder, Dr Paul Tunnah, chats with the chief medical officer of Senseonics. Francine Kaufman discusses how Senseonics is helping patients monitor their diabetes with the first fully implantable long-term continuous glucose monitoring (CGM) system. Monitoring glucose values is necessary for diabetes patients, and technologically […]

  • UK accelerates COVID booster plans in response to Omicron

    The UK looks set to extend its COVID-19 booster vaccination programme to all over-18s, as the number of cases of the new Omicron variant of SARS-CoV-2 has reached double figures. The gap between second doses and boosters is also being reduced from six to three months in an attempt to get as much protection in […]

  • Health literacy for the intellectually disabled: is pharma doing enough?

    What is health literacy and why is it important? Health literacy (HL), defined by the CDC as the degree to which individuals have the ability to find, understand and use information and services to inform health-related decisions and actions for themselves and others, is a valuable tool against health inequalities and negative patient outcomes. Low […]

  • Leveraging real-world data to meet payers’ needs

    Payers are becoming savvier in accepting real-world data. Certara’s Lee Stern and Shawn Bates discuss the challenges and how pharma can use real-world data to meet payers’ needs. For years, clinical trial data was king. But as healthcare costs continue to be squeezed, there is pressure on pharmaceutical companies to actually deliver on clinical trial […]

  • Time for a new model in patient access

    Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.   Why is a new access model so pressing, and has the pandemic accelerated the situation? Yes, it has. Although the need for a change in the […]

  • EU authorises first COVID-19 vaccine for 5 to 11 year olds

    The European Medicines Agency (EMA) has approved Pfizer and BioNTech’s COVID-19 vaccine Comirnaty for children between the ages of five and 11, as EU countries struggle to cope with rising infection rates. The EU regulator said that the under-12s should get a lower dose of the vaccine – 10 mcg rather than 30 mcg – […]

  • New COVID variant ‘may sidestep vaccine protection’

    A new variant of COVID-19 identified in Botswana with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines. The B.1.1.529 variant has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date, although it’s not yet clear if it […]

  • Time to take patient engagement to the next level

    Patient engagement in pharma is evolving, with some companies doing it better than others. Envision Pharma Group’s Dawn Lobban and Sarah Avent discuss the need to engage with patients at every level for holistic inclusion of the patient voice in order for pharma to become truly patient-centric. The Covid pandemic has sparked people’s interest in […]

  • Patients want to be heard. Is pharma listening?

    A common theme heard from the advocacy groups AXON works with is “Nothing for us without us,” says Natalie Turner, director at AXON, a global healthcare communications agency. Patients want to be part of the healthcare conversation and genuinely heard by those who make the final decisions, but pharma does not always understand how to […]

  • FDA, CDC COVID jab decisions ‘will simplify booster messaging’

    Three hurdles to allowing booster COVID-19 vaccinations for all adults in the US fell in swift succession on Friday, clearing the way for wider use of the Pfizer/BioNTech and Moderna shots. The FDA cleared emergency use of the two vaccines on Friday, which was swiftly followed by a recommendation from a Centres for Disease Control […]

  • Three views on technology improving clinical trial efficiency

    Marie Emms, vice president of site and patient participation at Syneos Health, tells us technology helped increase patient enrolment, improve diversity and inclusion, and boost retention rates for clinical trials after the pandemic. Still, she says a lot needs to be done to continue this upward trajectory. “There’s an acknowledgement among companies that the paradigm […]

  • Emerging from the shadow of COVID-19

    We now have a unique opportunity to re-discover what matters most to patients, says Alnylam’s Kasha Witkos. In the biotech industry, if you are not motivated by helping patients and potentially transforming their lives, then you’re in the wrong job. Yet understanding what people go through on their journey – particularly those living with a […]

  • Parliamentary probe finds racism evidence in NHS sickle cell care

    Patients with sickle cell disease are facing racism in the NHS that is putting their lives a risk, claims a new report.  The All-Party Parliamentary Group (APPG) document – entitled No One’s Listening and partnered with the Sickle Cell Society – found “serious care failings” in acute services and evidence of attitudes underpinned by racism […]

  • US court halts Biden’s COVID shots plan for companies

    The US Federal Court of Appeals has issued a temporary stay on President Joe Biden’s plan for mandatory COVID-19 vaccinations for employees of businesses. The mandate says that workers in privately-owned businesses with over 100 employees would have the be fully vaccinated by 4 January, or be required to take weekly COVID-19 tests and wear […]

  • Study shows HPV jab almost 90% effective at preventing cervical cancer

    Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The jabs with have been offered by the NHS to girls between the ages of 12 and 13 since […]

  • US backs COVID jabs for young kids – should others follow?

    The US is now pressing ahead with plans to extend its COVID-19 vaccination campaign to younger children aged five and over, prompting a debate about the policy in other countries. It follows the decision by Centers of Disease Control and Prevention (CDC) Director Rochelle Walensky to back a widening of vaccination shot from the current […]

  • COVID jabs much more effective than virus at preventing infection

    A US study has found that the immunity afforded by COVID-19 vaccines is much stronger than that stimulated by infection with SARS-CoV-2 in unvaccinated individuals. The report by the Centre for Disease Control and Prevention (CDC), based on an analysis of dozens of research studies and its own data, suggests that both vaccination and infection […]

  • Patient engagement strategies: the pharmaphorum podcast

    This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate. Here he takes a helicopter view of patient engagement in a discussion with MSD’s European lead for patient innovation Paul Robinson, that’s moderated by pharmaphorum’s former […]

  • Deep Dive: Patients and Partnerships

    As the world is slowly, gradually, hopefully emerges from the shadow of COVID-19 there’s a unique opportunity to re-discover what matters most to patients. In this issue there are insights from Astellas and Alnylam, plus informed commentary on health literacy, patients’ role in the healthcare conversation and we also look at R&D innovation in areas […]

  • CDC director backs COVID-19 jab for 5 to 11s, plus a fourth shot

    The US looks set to see a big expansion of the country’s COVID-19 vaccination drive, with shots looking likely for children aged five to 11 as well as a fourth dose for adults who are immunocompromised. FDA advisors gave a green light to Pfizer and BioNTech’s COVID-19 vaccine Comirnaty for children in that younger age […]

  • FDA advisors mull use of Pfizer/BioNTech COVID-19 jab in kids

    FDA advisors will meet later today discuss the possibility of authorising Pfizer and BioNTech’s COVID-19 vaccine Comirnaty in children as young as five years old. If the Vaccines and Related Biological Products Advisory Committee (VRBPAC) gives the go-ahead, the FDA could approve emergency-use of Comirnaty in five to 11-year-olds in a matter of days, extending […]

  • Joining forces can benefit both patients and pharma companies  

    By engaging in a dialogue, patients and pharma companies can have a mutually beneficial relationship, Health Union’s Jack Barrette said at HLTH’s patient engagement track, hosted by MedCity News. Not only can patients help mold clinical trials, but they can help companies improve their patient education efforts.

  • FDA okays Moderna, J&J COVID jab boosters, plus ‘mix and match’

    The FDA has authorised booster shots with Moderna and Johnson & Johnson’s COVID-19 vaccines, a month after giving the go-ahead to a third-dose of Pfizer/BioNTech’s shot. It has also authorised the use of different jabs as boosters than those people received for their primary vaccination – the so-called ‘mix and match’ strategy – on the […]

  • How to increase the coverage of healthcare professionals with omnichannel marketing approach

    How to increase the coverage of healthcare professionals with omnichannel marketing approach The way of reaching and targeting healthcare professionals and patients is transforming; it is mostly linked to the changing nature of their behaviors, preferences, and priorities. The pandemic has boosted the value of online engagement along with the focus shifted to remote means […]

  • Novartis-backed project mobilises patient power against heart disease

    Novartis has joined forces with a group representing cardiovascular disease patients organisations to push for changes in how health systems handle the world’s number one killer. The Invisible Nation partnership with Global Heart Hub aims to reduce 15 million deaths that occur each year due to atherosclerotic cardiovascular disease (ASCVD), according to the Swiss pharma […]

  • Make locally led public health ‘business as usual’, says report

    COVID-19 proved the value of locally led, place-based public health – but teams need long-term funding and support if they are to take their place as an essential cog in the ICS machine. Local public health teams have been acting as “linchpins” during the pandemic, building cross-sector relationships to respond to the immediate crisis, as […]

  • FDA panel backs booster shot for J&J COVID-19 vaccine

    An FDA advisory committee voted unanimously in favour of a booster dose of Johnson & Johnson’s one-shot COVID-19 vaccine on Friday, as panellists suggested it should have been used as a two-dose regimen from the start. The verdict – which came the day after a third dose of Moderna’s two-shot vaccine was also backed by […]

  • Are You Speaking a Patient’s Language?: 5 Terms Used By Patients

    Health journeys can be complex, sometimes more complex than a Rube Goldberg machine or spelling, say, embourgeoisement or consanguineous. And certain aspects of living with a chronic health condition – be that a symptom, side effect, emotional experience or other quality of life impact – can be hard to put into words. Over time, especially […]

  • What does the future of European healthcare look like?

    After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long term? COVID has taught us that future proofing healthcare systems has to be everyone’s main priority in the coming years. That’s according to the speakers at a roundtable session, held as part of the Reuters Events: Pharma […]

  • ‘Build back better’ cannot mean longer waiting times for change

    Global Blood Therapeutics (GBT) UK general manager Nigel Nicholls discusses the impact of COVID-19 for sickle cell patients in the UK. If the COVID-19 pandemic has shown us anything, it has highlighted the extent to which health inequity plagues our society. Although the Government, public and health care system have started to wake up to […]

  • Preparing for a pandemic starts with creating a mentally resilient society

    Janssen UK & Ireland’s managing director Gaëtan Leblay discusses the importance of maintaining the spotlight on our mental health post-pandemic, and why we must hone our mental resilience for possible future health crises. Our day-to-day life now looks significantly different compared to two years ago – without question, the pandemic has affected us all. One […]

  • GSK’s malaria vaccine gets WHO okay for mass rollout

    The WHO has given a green light to widespread use of GlaxoSmithKline’s malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. The RTS,S/AS01 vaccine – also known as Mosquirix – will be administered to children living in sub-Saharan Africa and other regions with moderate to high […]

  • The ‘patient of the future’ is driving radical innovation in healthcare

    Digital data collection, utilisation of real-word data and patient-centric thinking will all contribute to the rapid development of a new healthcare landscape, says Debiopharm Innovation Fund’s Tanja Dowe. In recent years, we have seen thinking shift from focusing on a disease’s treatment to seriously considering the wider potential for its prevention, enabled by dramatic advances […]

  • EU backs broader use of Comirnaty as COVID booster than US

    The EMA has given the go-ahead to the use of Pfizer and BioNTech’s COVID-19 vaccine Comirnaty as a booster for all people aged 18 or more, but says EU member states must decide for themselves whether to make a third dose available to their citizens. The regulator’s human medicines committee (CHMP) said that a third […]

  • Novartis tightens up its COVID-19 vaccine policy for staff

    Novartis has joined a growing number of companies insisting that its workforce is double vaccinated against COVID-19 if they want to work at one of its sites. The Swiss pharma group had earlier said it would require staff to either be vaccinated or have a negative COVID-19 test result within the last 14 days before […]

  • Blood Cancer UK: Hopes for our community’s future in the time of COVID

    This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness Month, Blood Cancer UK’s Kate Keightley explains the need for better awareness and understanding of this common, but less-understood disease. Blood cancer is the fifth most common cancer in the UK and the third most deadly, killing […]

  • FDA posts guidance on mining real-world data from health records

    There is a lot of discussion about the power of drawing out insights from information hidden within electronic health records and insurance claims, but little regulatory guidance on how that should be undertaken. Now, the FDA has published its first take on sourcing real-world data (RWD) from EHRs and medical claims, setting out its thinking […]

  • England’s cancer therapy backlog ‘could take more than a decade to shift’

    A new report has suggested it could take until 2033 to clear the backlog of cancer treatment in England caused by the pandemic. The analysis by the Institute for Public Policy Research (IPPR) and Carnall Farrar (CF) consultancy suggests that timeline will be the result if hospitals can operate at a level 5% above what […]

  • Social Health: The New Patient Journey

    Access to online social connections has transformed the patient journey, and your brand strategy can evolve with it to effectively meet patients where they are. Health Union recently surveyed 2,371 patients across a diverse representation of health conditions to better understand how social health – the digital means by which health consumers engage with each other […]

  • Amnesty says COVID jab producers are causing human rights crisis

    Amnesty International has slammed the six pharma companies behind the bulk of COVID-19 vaccine supplies of for not agreeing to waive their intellectual property rights and share the technology behind them. The charity says AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax, and Pfizer are fuelling an “unprecedented human rights crisis” as a result and their […]

  • Addressing the HIV epidemic in Eastern Europe and Central Asia

    Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021 marks 40 years since the first cases of HIV were reported. In that time, over 79 million people have been diagnosed with HIV, with more than 36 million dying from AIDS-related illnesses, more than any other infectious […]

  • Study finds 10% of medicines in England are overprescribed

    An alarming number of people in England are being prescribed medicines unnecessarily, which could harm their health, according to a UK government review. The study, led by the Chief Pharmaceutical Officer for England Dr Keith Ridge, estimates that 10% of items dispensed in primary care are inappropriate or could be better served with alternative treatments. […]

  • It’s time to do better for patients with rare neurological disorders

    Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to clinical trials for all patients with rare CNS conditions. Rare diseases impact more than 30 million Americans, and 400 million people around the globe. Less than 5% of the more than 7,000 rare diseases have approved treatments. […]

  • Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11

    With positive phase 2/3 results for their COVID-19 vaccine Comirnaty in hand for the five to 11 age group, Pfizer and BioNTech are planning to move swiftly ahead with a filing for emergency use that could be approved in a matter of weeks. The data is the first generated with any COVID-19 vaccine in this […]

  • Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11

    With positive phase 2/3 results for their COVID-19 vaccine Comirnaty in hand for the five to 11 age group, Pfizer and BioNTech are planning to move swiftly ahead with a filing for emergency use that could be approved in a matter of weeks. The data is the first generated with any COVID-19 vaccine in this […]

  • A defining characteristic of successful patient support programs is the level of cross-functional collaboration

    There is a distinct difference between outstanding patient support programs and less effective programs. A defining characteristic of successful programs is the level of cross-functional collaboration. By following the six strategies in this white paper, pharmaceutical companies can improve collaboration, enhance the patient experience, better protect patient data, reduce risk, improve compliance—and improve the overall […]

  • Taking stock of NHS medicines optimisation

    Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at local level, says NHS Gloucestershire CCG’s Ellen Rule. Medicines optimisation aims to improve health outcomes, service quality, and sustainability by ensuring patients are taking […]

  • Coalition formed to represent patient interests in digital health

    Not enough is being done to ensure that patient voices are included in policymaking around digital health, says a new patient organisation in the UK, which aims to set that situation right. The Patient Coalition for AI, Data and Digital Tech in Health has brought together members of patient organisations, medical colleges and health charities […]

  • Astellas reports fourth death in halted gene therapy trial

    There has been a fourth patient fatality in Astellas’ clinical trial of its AT132 gene therapy for the rare disease X-linked myotubular myopathy (XLMTM), which has been halted twice due to safety concerns. The latest suspension came after abnormal liver function tests (LFTs) were seen in a boy receiving the gene therapy, who has since […]

  • UK poised to announce booster COVID jabs for over-50s

    The UK government is due to announce a large-scale booster vaccine campaign against COVID-19 for all adults aged 50 and over later today, adding to its plan for third doses for people with weakened immune systems. The plan will see millions of doses of the Pfizer/BioNTech mRNA vaccine administered across the autumn and winter to […]

  • NHS England starts largest ever trial of Galleri cancer blood test

    A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects. Volunteers aged between 50 and 77 are being sought to trial the diagnostic developed by California biotech Grail, which spun out of Illumina in 2016 and […]

  • MHRA clears third doses of AZ, Pfizer COVID jabs

    The UK medicines regulator has cleared the use of a third dose of both the AstraZeneca and Pfizer COVID-19 vaccines, in readiness for a possible booster campaign ahead of the winter months. The decision means there is now no impediment to starting a booster drive – assuming the Joint Committee on Vaccination and Immunisation (JCVI) […]

  • Anxiety, Worry or Fear? Disappointment, Grief or Depression?

    By HANS DUVEFELT Especially in these strange and uncertain times, many people feel uneasy. Some of them come to us with concerns over their state of mind. In primary care, our job is in large part to perform triage. We strive to identify patients who need referral, medication or further evaluation. We also strive, or […]

  • AZ CEO Soriot urges caution on COVID booster doses

    The UK should think twice before backing widespread use of COVID-19 booster vaccinations, as to do so could place unnecessary burden on the NHS over the winter, according to AstraZeneca chief executive Pascal Soriot. In a letter to The Daily Telegraph newspaper with AZ’s head of biopharma R&D Mene Pangalos, Soriot write that the UK […]

  • UK pledges £5.4bn to NHS to ease COVID-19 treatment backlog

    NHS England will get an extra £5.4 billion ($7.5 billion) in funding over the next six months to respond to COVID-19 and address a backlog in care caused by the pandemic, according to the UK government. The total includes £1 billion to get delivery of routine surgeries and treatments to patients delayed by COVID-19 back […]

  • Does Our Healthcare System Work for the Most Vulnerable Americans?

    By DEBORAH AFEZOLLI, CARL-PHILIPPE ROUSSEAU, HELEN FERNANDEZ, ELIZABETH LINDENBERGER “Why did you choose this field?” Most physicians are asked this question at some point in their early careers. We are geriatrics and palliative medicine physicians, so when that question is posed to us, it is invariably followed by another: “Isn’t your job depressing?” No, our […]

  • Prof Nigel Osborne: Science is catching up with ‘medical music’

    The internationally recognised composer, peace worker and musical therapy pioneer tells pharmaphorum how his emerging field stands at an important threshold. History provides a wealth of commentary on the emotional value of music. One of the earliest came from Plato, who concluded that “rhythm and harmony find their way into the inward places of the […]

  • FDA firms up JAK inhibitor warnings after Xeljanz review

    The FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings for the drugs as well as others in the class after finding evidence of elevated risks of serious heart-related events. After looking at the data from Pfizer’s long-term, post-marketing safety study – ORAL Surveillance – the US […]

  • Taking a de-centralized approach to cure the Hepatitis C epidemic

    This year’s World Hepatitis Day theme, ‘Hepatitis Can’t Wait,’ stresses the urgency of testing and treating viral hepatitis, as well as removing the stigma surrounding the disease and providing support for patients. Treatment for hepatitis C has evolved dramatically over the past decade. The introduction of direct-acting-antivirals has revolutionized the treatment landscape, leading the World […]

  • More trouble for Astellas as AT132 gene therapy trial is halted again

    Astellas has halted dosing in a study of its AT132 gene therapy for the rare disease X-linked myotubular myopathy (XLMTM) for the second time after another serious adverse event (SAE) linked to possible liver damage. The ASPIRO trial of AT132 has been paused after abnormal liver function tests (LFTs) were seen in a patient receiving […]

  • Health Insurance is a Stumbling Block in Many Patients’ Thinking

    By HANS DUVEFELT I have a patient with no health insurance but a brand new Mercedes. He says he can’t afford health insurance. He cringes at the cost of his medications and our office visit charges. His car cost a lot of money and I know that authorized Mercedes dealers charge around $140/hour for their […]

  • UK real-world study finds COVID-19 jab protection wanes

    A study has found evidence that protection from the AstraZeneca and Pfizer/BioNTech COVID-19 vaccines starts fall off after a few months, but a UK government advisor says there’s no need to rush into a large-scale booster campaign. The results of the ZOE COVID study found that initial protection against infection a month after the second […]

  • Improving access to treatments in challenging markets

    The COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at pace and speed. Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute […]

  • Blueprints for UK pharma-NHS joint working

    Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As the NHS begins to recover from the biggest crisis in its history, the biopharmaceutical industry is stepping up to the plate to offer its support and a new online repository of […]

  • Does draft RCT guide set the scene for future trials?

    A common set of standards for randomised clinical trials (RCTs) aims to help researchers develop the drugs and interventions of the future – no matter what they do or where they are based. The Good Clinical Trials Collaborative (GCTC) has published a draft guidance document, and is asking for the life sciences sector to make […]

  • MHRA clears Moderna COVID vaccine for 12 to 17 year olds

    The Moderna COVID-19 vaccine has become the second jab to be authorised for use in England, Scotland and Wales in children aged 12 to 17 after getting the nod from the Medicines and healthcare products Regulatory Agency (MHRA). It joins the Pfizer/BioNTech vaccine in being an option for that age group, having been approved in […]

  • Pfizer, BioNTech file for FDA approval of COVID booster shot

    Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway. The two companies have submitted data from a phase 1 trial in support of the booster dose to the US regulator, and […]

  • FDA authorises COVID booster jabs for at-risk people

    The FDA has cleared the use of third dose of either the Pfizer/BioNTech or Moderna COVID-19 vaccines for people with weakened immune systems, but stopped short of a broader booster campaign. The emergency use authorisation (EUA) for the two mRNA-based vaccines has been amended so they can be used for solid organ transplant recipients or […]

  • Social Health: The Future of Healthcare Marketing

    With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers. As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself […]

  • Widespread use of health IT can cause burnout but also help curb it

    In a HIMSS 21 Digital session, panelists detailed the dichotomy of technology advancement for clinicians. Though technology has made it harder for them to disconnect from work leading to burnout, IT tools can also be used to identify pain points and implement solutions to alleviate stress.

  • BioNTech says repeat doses may be better than modified COVID-19 jab

    BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. The comments came on the German biotech’s second-quarter results call, during which BioNTech raised its forecasts for revenues it will book from sales of the vaccine to €15.9 billion (almost $19 […]

  • UK extends COVID vaccination to 16 and 17-year-olds

    The UK government has confirmed that the national COVID-19 vaccination campaign will be extended to include 16 and 17-year-old children, to tackle an increase in spread of the virus in younger age groups. The moves comes on the back of new advice from the Joint Committee on Vaccine and Immunisation (JCVI), which has concluded that […]

  • How to balance the patient voice atop the shifting plates of HTA

    The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances in medical science, from genomics and gene therapies to artificial intelligence (AI), have transformed the healthcare landscape, and triggered a review of NICE’s methods and processes. Consultation on the proposals […]

  • Germany confirms booster COVID jabs will start in September

    Germany’s health ministry has said it will start offering booster COVID-19 vaccines to vulnerable people from next month, amid concerns about rising cases of the delta variant of the coronavirus. Health Minster Jens Spahn said the decision was also taken because of concerns that the immune response stimulated by COVID-19 vaccines may start to diminish […]

  • Have a chat to help others through loneliness

    Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s gone’ comes to mind. It’s only now, having been isolated, that we can appreciate how much small moments of contact with family and friends can mean. Bristol Myers Squibb’s Janice Creasy discusses how  and help reduce feelings […]

  • Health literacy in the time of COVID-19

    In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health literacy has never been more important. Impetus Digital’s Natalie Yeadon explores why. Health literacy is a complex phenomenon that involves both individuals and their local […]

  • AZ says second COVID jab dose isn’t linked to rare clot reaction

    A new analysis has suggested that the rare blood clot side effects linked to AstraZeneca’s COVID-19 vaccine Vaxzevria don’t occur after a second dose. The study in The Lancet examined cases of thrombosis with thrombocytopenia syndrome (TTS) from an AZ database encompassing around 5.62 million people who had received two doses of Vaxzevria in the […]

  • Tackling the ‘disease of systemic racism’ in clinical trials

    A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into sharp focus by COVID-19. Tackling it, however, has not been easy, thanks in no small part to the reasons being as complex as they are multi-faceted. But, according to the […]

  • Rapid COVID immune status test launched in UK, Ireland

    You’ve had your two COVID-19 jabs, but are you actually protected against infection? That’s a question that a fingerprick test launched today in the UK and Ireland could help to answer. The test – originally developed by US manufacturer Chembio Diagnostics – has been introduced into the UK and Irish markets by Guilford-based Luas Diagnostics […]

  • Study finds jabs cut severe variant COVID disease after one shot

    A real-world study carried out in Canada had found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce the chances of being hospitalised or dying from variants of concern dramatically, even after a single dose. AstraZeneca’s Vaxzevria was found to 87% effective after against the delta variant, which is now thought to be one of […]

  • Build back better: US pharma and the future of healthcare

    America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged […]

  • Build back better: US pharma and the future of healthcare

    America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged […]

  • UK funds ‘long COVID’ research drive as restrictions ease

    The UK government has provided almost £20 million ($27 million) in funding for 15 research projects aiming to look into the causes of long COVID, improve diagnosis and find new treatments for the condition. Long COVID is the term used to described people who still suffer from fatigue and other symptoms like breathlessness and muscle […]

  • UK funds ‘long COVID’ research drive as restrictions ease

    The UK government has provided almost £20 million ($27 million) in funding for 15 research projects aiming to look into the causes of long COVID, improve diagnosis and find new treatments for the condition. Long COVID is the term used to described people who still suffer from fatigue and other symptoms like breathlessness and muscle […]

  • The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

    During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell targeted therapies and tumor necrosis factor (TNF) inhibitors have given patients therapeutic options beyond traditional treatments such as topical steroids, tar preparations, oral systemics, and light […]

  • The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

    During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell targeted therapies and tumor necrosis factor (TNF) inhibitors have given patients therapeutic options beyond traditional treatments such as topical steroids, tar preparations, oral systemics, and light […]

  • The Case to Realign Parkinson’s Disease Research

    By STEVEN ZECOLA If asked, the leaders of the research organizations working on Parkinson’s disease would say that they have made tremendous progress and are optimistic on finding a cure for the disease.  In truth, this viewpoint understates the magnitude of the challenge and results in insufficient resources being devoted to PD. Given the size […]

  • UK study raises hopes of long COVID test within months

    A diagnostic test to detect long COVID could be available within six to 12 months, following the discovery that patients with the chronic condition have distinctive antibodies in their blood.  Researchers at Imperial College London (ICL) led by Professor Danny Altmann told the BBC’s Panorama programme that they have identified a pattern of antibodies in […]

  • EMA finds possible link between mRNA COVID jabs and myocarditis

    The EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based vaccines for COVID-19 and rare cases of heart inflammation.  According to the EMA’s pharmacovigilance risk assessment committee (PRAC), labelling for Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax should be updated to reflect “very rare cases” of myocarditis and pericarditis […]

  • How digital pathways are changing healthcare

    As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a more connected ecosystem between doctors, patients and pharma. Ampersand Health has been working in the space since 2015 and has seen it evolve from a niche approach with limited acceptance […]

  • Israel says Pfizer jab less effective against COVID-19 delta

    The Israeli Ministry of Health has reported data suggesting that the efficacy of the Pfizer/BioNTech COVID-19 vaccine has become less effective at preventing the spread of the coronavirus after the emergence of the delta variant. The vaccine still seems to be able to prevent hospitalisation and severe cases of COVID-19, but its efficacy in preventing […]

  • Why I Seldom Recommend Vitamins or Supplements

    By HANS DUVEFELT People here in northern Maine, as in my native Sweden, don’t get a whole lot of natural sunlight a good part of the year. As a kid, I had to swallow a daily spoonful of cod liver oil to get the extra vitamin D my mother and many others believed we all […]

  • UK body recommends COVID booster campaign in autumn

    The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive.  The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination […]

  • UK body recommends COVID booster campaign in autumn

    The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive.  The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination […]

  • Health Union Acquires WEGO Health

    Health Union, the leader in building online health solutions for people living with chronic conditions, today announced that it has acquired WEGO Health, the world’s largest network of patient leaders – advocates, community leaders, creators and influencers. Combining Health Union’s targeted scale and depth in the condition experience with WEGO Health’s breadth of patient leaders […]

  • Supporting and empowering carers to make their voices heard

    There are an estimated nine million carers in the UK, and their contributions to society, individually and as a group, are unparalleled. Nadine van Dongen and Antonella Porta remind us why carers are the unrecognised backbone of our society. Every day, carers look after some of the most vulnerable people around us, attending to their […]

  • Privacy issues widespread with digital health apps, says BMJ

    Developers of mobile health apps are comprehensively failing to safeguard the privacy of users, according to a study by researchers in Australia. The team from Macquarie University compared 15,000 free mobile health (mHealth) apps available on the Google Play store and compared their privacy practices to those found in 8,000 non-health apps, finding “serious problems […]

  • COUCH Health Engages Mark Duman as Chief Strategy Officer

    COUCH Health, a patient engagement agency, announced the appointment of Mark Duman as its Chief Strategy Officer (CSO). Taking charge of strategy development and execution for COUCH Health, Mark will oversee the expansion of COUCH Health’s mission to contribute to inclusive clinical trials that prioritise the patient experience. Mark will report directly to CEO Ash […]

  • AZ’s COVID jab tackles delta variant, but antibody fails clinical trial

    The delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but there is some good news – the AstraZeneca/Oxford University vaccine seems to offer a high level of protection against it. Real-world data from Public Health England (PHE) suggests that the vaccine prevents 92% of hospitalisations in patients […]

  • J&J must ditch 60m COVID jabs made at US plant, but 10m are okay, says FDA

    The failings at a Baltimore, US factory making Johnson & Johnson’s COVID-19 vaccine mean that millions of doses of the shot will have to be jettisoned, according to an FDA update. The problems at the plant run by contract manufacturer Emergent BioSolutions first emerged a few weeks ago, after an FDA inspection uncovered a string […]

  • US orders 500m Pfizer/BioNTech COVID jabs for developing nations

    The US government will buy 500 million more doses of the Pfizer/BioNTech COVID-19 vaccine that will be given to around 100 countries via the COVAX donation programme over the next two years. Pfizer and BioNTech are providing 200 million doses this year, and another 300 million in the first half of 2022, at a not-for-profit […]

  • Study links AstraZeneca COVID-19 shot to bleeding disorder ITP

    Researchers in Scotland have identified a possible link between the Oxford University/AstraZeneca COVID-19 and a mostly mild and generally treatable bleeding disorder. The scientists examined real-world public health data from all individuals in Scotland who received either the AZ or Pfizer/BioNTech vaccines up until 14 April and found a possible association between the AZ shot […]

  • Ensuring accessibility: Crossing the digital divide in healthcare

    “Rarely does the answer come from the boardroom” – what can user experience teach us about building accessible digital health? No one should be left behind as the world embraces digital healthcare say leading user experience, voices. The experts discussed the benefits and merits of co-creation during a session on bridging the digital divide, held […]

  • NHS patient data upload delayed by two months, says UK

    The UK’s decision to set back the start date of a new patient data-sharing scheme by two months has been welcomed by privacy campaigners, who have claimed it was being rushed through without sufficient public scrutiny. The centralised database of medical records from 55 million people was due to come online on 1 July, but […]

  • Millions of COVID jabs risk being wasted, says UNICEF

    Rich nations are being asked to start donating COVID-19 vaccines to other parts of the world straight away, to avoid a glut of surplus supply in the coming months that could see millions of doses going to waste. In an open letter, UNICEF and a host of A list celebrities argue that G7 countries will […]

  • Study finds “alarming” hike in antidepressant costs during COVID-19

    Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs. The team from the University of Huddersfield said the findings highlight an “urgent need” for new mental health strategies to make sure antidepressants are being used appropriately, particularly […]

  • Value-based healthcare: Pandemic learnings and future musings

    In the second part of our series from the ‘Patient Experience: Empathy and Innovation’ Digital Summit, we look at what COVID-19 can teach us about designing truly value-based healthcare.  Discussions of value-based healthcare provider contracts are often technical and far removed from the patient – but COVID has given us a chance to connect the […]

  • UK is talking to AstraZeneca about beta variant COVID jab

    The UK government is talking to AstraZeneca about ordering additional doses of its COVID-19 vaccine that will target the beta variant of SARS-CoV-2 virus first identified in South Africa, according to Health Secretary Matt Hancock. The AZ/Oxford University vaccine and other shots from Pfizer/BioNTech and Moderna are known to have less efficacy against the beta […]

  • Closing the feedback loop to drive patient experience improvements

    Is collecting near real time data the key to unlocking improvements in patient experience and national benchmarking? Small things can go a long way in terms of improving patient experience, but healthcare facilities cannot fix what they don’t know is broken. In the first of our series of articles from the Patient Experience: Empathy and […]

  • Off Our Chests: No Secrets Left Behind

    By CHADI NABHAN She was a successful corporate lawyer turned professional volunteer and a housewife. He was a charismatic, successful, and world-renowned researcher in gastrointestinal oncology. He was jealous of all breast cancer research funding and had declared that disease his nemesis. They were married; life was becoming a routine, and borderline predictable. Both appeared […]

  • Campaigners challenge NHS England’s latest plan to share patient data

    Remember the debacle? Now, a new move by NHS England to move the records of 55 million patients into a database that will be accessible by third-party companies is under fire by privacy campaigners, who claim it could be unlawful.  The new General Practice Data for Planning and Research (GPDPR) service was unveiled earlier […]

  • Moderna will file COVID-19 jab for teens after trial shows 100% protection

    Moderna’s COVID-19 vaccine has joined the Pfizer/BioNTech jab in showing efficacy in younger patients in clinical trials, setting up an emergency use filing early next month. The results of the phase 2/3 TeenCOVE study in more than 3,700 adolescents aged 12 to 17 revealed no cases of COVID-19 after two doses of the mRNA-1273 shot, […]

  • Safety of mRNA COVID-19 jabs backed, despite myocarditis cases

    As US and EU health regulators review cases of heart inflammation seen in young people administered mRNA-based COVID-19 vaccines from Pfizer/BioNTech and Moderna, cardiologists have come out in favour of the jabs. The American Heart Association (AHA) and American Stroke Association (ASA) have issued a statement saying that the benefits of the vaccines “enormously outweigh […]

  • UK says Pfizer, AZ COVID-19 vaccines work against Indian variant

    People who have received two doses of the AstraZeneca or Pfizer/BioNTech COVID-19 vaccines have good protection against the Indian variant of SARS-CoV-2 , according to new UK data. The Pfizer/BioNTech shot provided 88% protection against the B.1.617.2 variant first identified in India and currently gaining ground across the UK and other countries around the world, […]

  • UK booster trial will test value of third COVID jab dose

    All seven COVID-19 vaccines ordered by the UK government will be tested in a new trial that will see whether they can be used as a third booster dose to protect against new variants.  The Cov-Boost trial is thought to be the first in the world to try to generate data on the value of […]

  • “Tell Me More”

    By HANS DUVEFELT Words can be misleading. Medical terms work really well when shared between clinicians. But we can’t assume our patients speak the same language we do. If we “run with” whatever key words we pick up from our patient’s chief complaint, we can easily get lost chasing the wrong target. Where I work, […]

  • UK highlights life sciences’ key role in post-COVID recovery

    The UK government used the Queen’s Speech to set out its ambition to make the country a leader in life sciences, garnering a warm response from industry groups.  The speech – an opportunity for Boris Johnson’s government to set out its plans for the year ahead after consolidating its position in last week’s local elections […]

  • How a lack of mental health diagnosis is affecting young men

    As lockdown gradually eases, things are starting to look up but the lasting impact COVID-19 has had on our wellbeing remains. During Mental Health Awareness Month we look at the mental health stigma amongst men. To say we’re in the midst of a mental health crisis is not an exaggeration. Mental health concerns have been […]

  • EMA panel probes heart inflammation with Pfizer/BioNTech COVID vaccine

    A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot.  The Pharmacovigilance Risk Assessment Committee (PRAC) says it is aware of cases of myocarditis and pericarditis – inflammation of the heart muscle and membrane around the […]

  • Why relationships are key in rare disease patient engagement

    Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a broader view of their lived experiences, says Xperiome’s Jeremy Edwards. It is difficult to get data on rare diseases and the people who live with them by their very nature. […]

  • UK ‘planning to widen AstraZeneca COVID jab restrictions’

    Reports are emerging that the UK may join other countries in imposing restrictions on the use of AstraZeneca’s COVID-19 vaccine in younger people, after a fresh look at the risks and benefits of the shot.  The Joint Committee on Vaccination and Immunisation (JCVI) said last month that it is preferable for adults aged under 30 […]

  • Not just COVID-19 vaccines: 5 things that cause blood clots

    Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the most common causes of blood clots and how we can prevent them. Over 11 million doses of COVID-19 vaccines have been given across the UK, with blood clotting observed […]

  • 3 Considerations for Pharma Brand Strategy Success

    Change is coming in the digital marketing world whether you’re ready or not. New challenges are presented for marketers as privacy measures tighten and we say goodbye to cookies, yet this impending farewell also presents an invaluable opportunity to rejuvenate your pharma brand strategy. As healthcare marketers prepare for the switch to flip, one thing is […]

  • Janssen’s Darzalex (daratumumab, SC) Combination Regimen Receives Health Canada’s Approval for Patients with Newly Diagnosed Light Chain Amyloidosis

    Shots: The approval is based on results from the P-III ANDROMEDA (AMY3001) study involves assessing the safety and efficacy of Darzalex (1800mg, SC, qw) + bortezomib, cyclophosphamide, and dexamethasone (VCd) vs VCd alone in 388 patients with newly diagnosed AL amyloidosis The study showed higher hematologic response rate in ITT population (53% vs 18%), patients […]

  • Zogenix Presents Results of Fintepla’s (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients, Caregivers, and Families at AAN 2021

    Shots: The P-III study is designed to assess caregivers’ perspectives on the long-term seizure & non-seizure-related benefits of Fintepla on patients with Dravet syndrome and on their caregivers and families Results: seizure-related benefits noted by caregivers include a reduction in frequency, seizure activity, and shorter recovery time while non-seizure benefits include improvements in executive functions […]

  • World Orphan Drug Congress USA Virtual 2021

    On Wednesday, April 28th, the World Orphan Drug Congress USA is being held online for free! The conference brings together pharma, biotechs, government, payers, investors and patient/patient advocates in the rare disease space to discuss the latest developments that will lead to the future of orphan drug development. We are thrilled to announce some amazing speakers […]

  • The Pain Is In Your Brain: Your Knees Know Next to Nothing

    By HANS DUVEFELT A “frozen shoulder” can be manipulated to move freely again under general anesthesia. The medications we use to put patients to sleep for such procedures work on the brain and don’t concentrate in the shoulder joints at all. An ingrown toenail can be removed or an arthritic knee can be replaced by […]

  • AstraZeneca’s Tagrisso (osimertinib) Receives the NMPA’s Approval for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

    Shots: The approval is based on results from the P-III ADAURA trial assessing Tagrisso (80mg, qd) vs PBO in 682 patients with stage IB, II, IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated for three years or until disease recurrence Results: Improvement in DFS in all population, 83% reduction in the […]

  • US seeks halt on J&J COVID vaccine rollout as clot concerns spread

    US health authorities have recommended pausing dosing with Johnson & Johnson’s COVID-19 vaccine as they investigate cases of blood clots also observed in some people taking the AstraZeneca shot.  The FDA said there had been reports of six cases of cerebral venous sinus thrombosis (CVST) associated with low blood platelet counts (thrombocytopenia) out of more […]

  • Cytisinicline – the solution to stop smoking?

    Whether present in electronic or combustible cigarettes, nicotine is a highly addictive substance. Dr Cindy Jacobs, chief medical officer of Achieve Life Sciences discusses the potential of cytisinicline therapy for smoking cessation.  Although e-cigarettes are considered a less dangerous alternative to combustible cigarettes, they can still result in, or sustain, nicotine addiction, for which the […]

  • The power of communication: engaging diverse groups in healthcare

    Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society – especially in healthcare. Page & Page’s Lisa Jane Lishman outlines why communication and the strategies behind it need to be more personal to ensure that people […]

  • UK will offer under-30s alternative to AZ’s COVID jab

    The UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca COVID-19 vaccine, because of evidence linking it to rare blood clots.  Updated figures from the Medicines and Healthcare products Regulatory Agency (MHRA) reveal 79 people experienced blood clots after receiving a dose of Vaxzevria (AZD1222), with 19 […]

  • Paediatric trial of AZ COVID jab ‘halted as a precaution’

    Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a possible link to rare cases of blood clotting is investigated by the UK drugs regulator.  Around 300 volunteers have been enrolled into the trial, but investigators have decided to pause dosing with the Oxford/AZ vaccine while they […]

  • Could Moderna shot save UK’s under-50s COVID vaccination push?

    People in the UK will start receiving doses of Moderna’s COVID-19 vaccine in around two weeks’ time, according to vaccines minister Nadhim Zahawi. The roll-out of the third coronavirus shot will come as the UK exits its second lockdown round, and in time to offset an anticipated dip in supply of the Oxford University/AstraZeneca AZD1222 […]

  • Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases

    Shots: The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources, financial contribution, and experience from both the company The alliance strengthens n-Lorem’s mission to bring immediate hope and rapid treatment to ultra-rare disease patients in need n-Lorem Foundation provides a free and lifetime supply of ASO […]

  • Janssen and SpringWorks Reports Dosing of First Patient in P-Ib trial for Nirogacestat + Teclistamab to Treat Relapsed or Refractory Multiple Myeloma

    Shots: The first patient has been dosed in P-Ib trial evaluating SpringWorks’ Nirogacestat (GSI) + Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. Janssen assumes all costs of study & other expenses related to the supply of nirogacestat In preclinical models, Nirogacestat increased the cell surface density of BCMA, reduced the […]

  • EMA backs safety of AZ COVID-19 jab in all age groups

    The head of the EMA has reiterated that there is no evidence to limit the use of AstraZeneca’s COVID-19 vaccine in any age group, after Germany and Canada imposed restrictions in younger patients.  “Our position has not changed” from a safety update two weeks ago, said Emer Cooke at an EMA press conference today. “According […]

  • UK government launches new office to “level up” nation’s health

    The government has continued its shake-up of UK health authorities with the creation of the Office of Health Promotion (OHP), which will focus on issues like obesity, mental and sexual health, and promoting physical activity.  The OHP will take over the health improvement remit currently the responsibility of Public Health England (PHE), and will “lead […]

  • BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma

    Shots: The P-II/III RELATIVITY-047 (CA224-047) study involves assessing the FD combination of relatlimab (160 mg) + Opdivo (480mg) vs Opdivo (480mg, IV, q4w) alone in 714 patients in a ratio (1:1) with previously untreated metastatic or unresectable melanoma The study met its 1EPs of the PFS while the follow-up for 2EPs of OS and ORR […]

  • MHRA launches patient involvement pilot for drug applications

    The UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts made to involve patients in the drug development process.  The voluntary scheme by the Medicines and Healthcare products Regulatory Agency (MHRA) aims to inject a dose of “patient centricity” into medicines development – something that has been […]

  • The hidden danger of isolated congenital asplenia

    TEAM 4 Travis is an advocacy group with one objective – to ensure it doesn’t take an autopsy to diagnose isolated congenital asplenia. As part of our Patient Insights series, founder Allison Bones tells us why she is determined to stop history repeating itself. When Travis Bones died just days after his fourth birthday, his […]

  • Making a big impact in small patient populations

    Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves1. Advances in next-generation sequencing have shown that sequencing the whole genomes of large numbers of individuals in a standardized way can improve the diagnosis and treatment of patients with rare diseases. Scientists have […]

  • Making a big impact in small patient populations

    Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves1. Advances in next-generation sequencing have shown that sequencing the whole genomes of large numbers of individuals in a standardized way can improve the diagnosis and treatment of patients with rare diseases. Scientists have […]

  • Continuity of Care in a Pandemic: Reflecting on the Rise of Telehealth

    March 2021 comes with mixed emotions, as people across the United States reflect on one year of life in the era of COVID-19. From a rollercoaster of lockdown restrictions, isolation, mask-wearing and socially distancing, to finally experiencing a glimmer of hope with increasing vaccine distribution – it’s safe to say the past 12 months have […]

  • Continuity of Care in a Pandemic: Reflecting on the Rise of Telehealth

    March 2021 comes with mixed emotions, as people across the United States reflect on one year of life in the era of COVID-19. From a rollercoaster of lockdown restrictions, isolation, mask-wearing and socially distancing, to finally experiencing a glimmer of hope with increasing vaccine distribution – it’s safe to say the past 12 months have […]

  • States halting AZ jab a ‘disaster’ for EU’s COVID vaccination programme

    The decision by around a dozen EU countries to suspend dosing with AstraZeneca’s COVID-19 vaccine is facing criticism, amid fears that it could undermine the response to the pandemic in Europe.  Germany, France, Italy and Spain are among the member states that have announced a suspension of dosing with AZD1222 in the last 24 hours […]

  • Patient involvement in trial design: looking to the future

    COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. Speakers at the NIHR’s recent virtual event for the pharma industry discussed best practices for bringing patient insights into research. The pandemic has forced the industry to embrace virtual patient […]

  • EU regulators probe safety of AstraZeneca vaccine batch after blood clot reports

    European safety regulators have launched an investigation into the safety of a batch of the Oxford University/AstraZeneca COVID-19 vaccine, as countries including Denmark suspended its use as a precaution following reports of blood clots. Initial findings showed no issue with the shots suspended by Austrian authorities after a person was diagnosed with severe blood clotting […]

  • Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia

    Shots: The P-III REMDACTA study involves assessing Actemra/RoActemra (tocilizumab) + Veklury (remdesivir) vs PBO + Veklury in hospitalized patients with severe COVID-19 pneumonia receiving SOC The study did not meet its 1EPs i.e. improvement in time to hospital discharge up to day28 and failed to meet its 2EPs compared to Veklury alone. The findings will […]

  • Getting the 340B program back on track in 2021

    As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have been disproportionately impacted by COVID-19. That’s why it has never been more important for policymakers to ensure federal programs, like the 340B program, […]

  • Lymphoma Action – championing the patient voice in cell therapy

    Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill and Director of Operations and External Affairs Stephen Scowcroft believe it is essential to champion the patient voice in cell therapy. This thought leadership series has been paid for and developed with Kite, A Gilead Company. Lymphoma […]

  • How accidental advocacy is amplifying the GM1 voice

    Rare disease families need to stand up and be counted if they want things to change said mum and advocate Christine Waggoner. She spoke to pharmaphorum as part of our Patients Insights series. Like many “rare disease mums”, Christine is an accidental advocate. After her daughter, Iris, was diagnosed with a rare disease at five, […]

  • NIH abandons convalescent plasma trial in mild COVID

    Another trial of convalescent plasma in people with COVID-19 has missed the mark, this time in mild to moderate disease, further dashing hopes that the therapy could have an impact on the infection.  Convalescent plasma taken from recovered COVID-19 patients is laden with antibodies against SARS-CoV-2, and the hope was this could be used to […]

  • Providers look to predictive modeling to help rebuild finances in 2021

    After a challenging 2020, health systems are looking to deploy strategies for recovery, especially to bolster financial health. One strategy health executives are considering is investing in predictive modeling technology that can help them manage patient demand and outcomes in the coming year.

  • Roche introduces 15-minute nasal COVID test in UK

    Roche Diagnostics has launched a 15-minute nasal antigen test for COVID-19 in the UK, and says it has millions of the kits available straight away to help the country recover from the pandemic.   The speedy test can turn around results within 15 minutes, without the need for processing swabs in a lab, and only […]

  • BMS’ Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP’s Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

    Shots: The CHMP recommendation is based on P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC The P-III result showed improvements in PFS, OS and ORR with consistent efficacy benefits observed across key subgroups of patients and was well tolerated, with a low […]

  • BridgeBio and Origin’s Nulibry (fosdenopterin) Receives the US FDA’s Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

    Shots: The FDA has approved Nulibry based on three clinical trials compared to data from a natural history study in patients with MoCD Type A The results from three clinical trials showed improvement in overall survival and an 82% reduction in the risk of death, @3yrs. probability of survival in rcPMP-treated patients (84% vs 55%), […]

  • Health at every size – making medicine weight inclusive

    UK-based doctor, Dr Natasha Larmie is on a mission to make medicine weight inclusive. Inspired by the Health at Every Size movement, Natasha is campaigning to take the weighing scales out of general practice and focus instead on health promoting behaviours. Last year, as the pandemic escalated worldwide, UK GP Dr Natasha Larmie embarked on […]

  • Building a better future for people with rare diseases in all four UK nations

    How has rare disease care changed over the last few years? And what might we expect from the next five? We attended the Rare Disease Day Virtual Parliamentary Event to find out. The rare disease community has a golden opportunity to transform the way care is delivered across all four UK nations – that’s according […]

  • Limited access to cancer biomarker testing in Europe, report finds

    There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report. The report from European Federation of Pharmaceutical Industries and Associations (EFPIA) shows the results of research conducted in 2020 to assess the availability, quality and reimbursement of biomarker tests […]

  • AZ COVID jab efficacy debate is hindering EU’s vaccine drive

    The spat between the EU and AstraZeneca over access to the company’s COVID-19 shot led to scathing remarks about its efficacy that now threaten to undermine the EU’s vaccination targets.  The European Commission approved AZ’s AZD1222 vaccine for use in the EU in all adults aged over 18 at the end of January, more than […]

  • Common but not normal: It’s time to talk about maternal mental health

    As part of our Patients Insights series, the founder and CEO of Motherhood Understood shares her experience of postpartum depression, talks about the power of peer support, and explains what the wider healthcare community could do to play their part. Within days of giving birth to her first child, Jen Schwartz’s fairy tale view of […]

  • Zynteglo halt re-ignites viral vector safety concerns; analysts

    Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface.  That’s the view of analysts at Jefferies, who suggest it could “re-ignite concerns over the […]

  • Scientists make case for one dose of Pfizer’s COVID jab to stretch supplies

    Two researchers have suggested that the second dose of Pfizer and BioNTech’s COVID-19 vaccine could be delayed, as this would increase the number of people that can be protected while supplies are limited without compromising its efficacy.  The two Canadian researchers – Danuta Skowronski and Gaston De Serres – make the suggestion in a letter […]

  • UK will start first COVID-19 challenge study “within a month”

    Sometime within the next few weeks, young and healthy volunteers will be deliberately exposed to the COVID-19 coronavirus in the UK in what looks set to be the first study of its type worldwide.  The human challenge study has just secured ethics committee approval and will recruit up to 90 volunteers aged 18-30 years, according […]

  • Relationship Advice: What Patients Want HCPs to Know About Satisfaction

    What aspects of a patient’s treatment matter most? For many, healthcare providers (HCPs) make a significant impact on how a person feels about their overall care plan; a positive HCP-patient relationship can help a person feel in control of their health and more prepared for the journey ahead, while a less than ideal HCP-patient relationship […]

  • Building early relationships: a gamechanger for pioneering rare disease treatment

    Advocacy groups play a crucial role in both driving access to innovative treatment and services and educating patients and caregivers on novel breakthroughs. On average, it takes more than four years to receive an accurate diagnosis of a rare disease.1 This diagnostic odyssey has pushed patients and caregivers online to self-diagnose and learn more about […]

  • COVID-19 increased demands on carers’ wellbeing, study finds

    COVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, according to a global study. Embracing Carers is a global initiative led by Germany’s Merck KGaA and is focused on recognising and raising awareness about the role of informal carers. It intends to develop solutions with global […]

  • Roche and PatchAi partner on digital tool for cancer patients

    Roche’s Italian subsidiary has joined forces with digital health startup PatchAi to roll out an app that aims to support people diagnosed with cancer. Roche and PatchAi have been working together on the Smart Health Companion (SHC), which was launched to oncology and haematology patients in July 2020, and will now step up their collaboration […]

  • Help Your Patient Be an RA Warrior

    By Mary Schmalfeldt, BSN, RN Clinical Support Educator, VMS BioMarketing Recently, I had an opportunity to do something for a friend I wish I could do for every person who receives a frightening or confusing new diagnosis such as rheumatoid arthritis (RA). Simply put, I let her talk. I listened to her fears and concerns, […]

  • Guinea declares Ebola epidemic following first deaths since 2016

    Guinea has officially declared it is dealing with an Ebola epidemic, after at least three people died from the virus. The BBC reported that these first deaths from Ebola since 2016 were linked to the burial of a nurse, where four others fell ill with diarrhoea, vomiting and bleeding. Newly developed vaccines will be supplied […]

  • Takeda Report Results of TAK-620 (maribavir) in P-III SOLCTICE Trial for the Treatment of Post-Transplant Patients with Cytomegalovirus Infection

    Shots: The P-III TAK-620-303 (SOLSTICE) trial involves assessing TAK-620 (400mg) vs conventional antiviral therapies (IAT) in HCT and SOT recipients in a ratio (2:1) with R/R CMV infection refractory with/ out resistance, to one or a combination of the conventional antiviral therapies The 1EPs study shows confirmed CMV viremia clearance @ 8wk; (55% vs 26.1% […]

  • Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems

    Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs.  Ipsen’s John Chaddock tells us why the company is investing heavily in neurotoxin research and how he hopes to raise awareness among young scientists and the NHS. When the COVID-19 pandemic first hit, […]

  • A study to avoid chemotherapy in patients with early HER-2+ breast cancer

    MEDSIR, a global company dedicated to independent clinical research in oncology, has initiated the PHERGain II clinical trial to demonstrate that in patients with HER2-positive early breast cancer with a good prognosis, a chemotherapy-free therapeutic approach can be as effective as the current standard of care, which involves the use of this generally more toxic […]

  • 5 Ways to Make Your Pharma Marketing More Personal

    Personalization in marketing–the practice of understanding and delivering content when and where people are ready to accept it–in any industry is key, but perhaps even more so in healthcare. If we’ve learned anything as marketers in 2020, this new landscape demands personalization to break through the noise and reach and engage with people during their […]

  • Why we need the human element of remote clinical trials

    Over the last year, we’ve noticed that “connectivity” doesn’t always equate to “connected” – and that’s just as true in the realm of clinical trials as it is in our personal lives. Amanda Barrell reports from a panel at the Patients as Partners Europe conference on remote clinical trials. Decentralised trials have been growing in […]

  • 23andMe goes public using Richard Branson’s blank cheque company

    DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. The agreement with Branson’s VG Acquisition Corp ties in with an emerging trend among life sciences companies to forego the usual initial public offering (IPO) […]

  • Merck’s Report Results of Keytruda (pembrolizumab) in Combination With Ipilimumab vs Keytruda Monotherapy in P-III KEYNOTE-598 for Metastatic Non-Small Cell Lung Cancer Patients

    Shots: The P- III trial involves assessing of Keytruda in combination with ipilimumab vs Keytruda monothx in 568 patients in a ratio (1:1) as 1L treatment for metastatic NSCLC patients without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1 Results: @ median follow-up (20.6 mos.); mOS (21.4 vs 21.9 mos.); mPFS (8.2 […]

  • Patients as Partners Europe: Are we doing patient centricity all wrong?

    To be truly patient centric, do we need to turn the current model on its head and work within a more free-thinking, free-speaking framework? Amanda Barrell reports from Patients as Partners Europe. Despite huge progress over the last decade, patient involvement in research is still largely in the hands of the pharmaceutical companies. That is […]

  • Mistrust in medical research: a patient perspective

    In medical research, trust has traditionally been hard-fought for. Terms like “lab rats” and “guinea pigs” are often used in conversations about clinical trials. For some communities, the historic unethical treatment of participants is also still a raw memory[1]. People tend to remember when things go wrong, and this casts doubt over procedures and leads […]

  • Unpacking rare diseases in the first edition of Delta magazine

    Welcome to Delta – the new Fishawack Health magazine. We’ve chosen to focus our first edition of the magazine on a topic close to our hearts, rare diseases. Rare diseases represent an incredibly high unmet need, not only due to the lack of therapies and the practical difficulties in diagnosis, but also in patients’ desire […]

  • UK is first European country to see COVID-19 deaths pass 100,000

    More than 100,000 people have died within 28 days of a positive COVID-19 test in the UK, the first European country to meet that grim milestone. The UK is only the fifth country after the US, Brazil, India and Mexico to pass that threshold, after a surge in cases following the holiday period around the […]

  • Real-world evidence: breaking boundaries in rare disease

    The COVID-19 pandemic has added a new layer of complexity to the drug development process. Launch timelines have been delayed and clinical trials have been postponed or suspended. As a result, life sciences companies are turning to novel methods of collecting clinical data and innovative trial design. The generation of data to show the significant […]

  • Patient partnerships: putting relevance into relationships

    There are perhaps two ways to look at 2020 – on the surface, it has been a year of pandemic health catastrophe, on a deeper level it has been a year where we finally acknowledged the fragility of health partnerships and the importance of good relationships between the pharmaceutical industry and the patients it serves. […]

  • Assessing physician practices and expectations in the post-COVID era

    The ongoing COVID-19 pandemic has affected the routines of many practicing physicians, including an impact on their prescribing decisions. New research from CRA shows that for many physician practices, prescribing has shifted based on route of administration. These changes, initially presumed to be temporary, may continue beyond the pandemic. As several COVID-19 vaccine candidates progress […]

  • 3 practical steps for improving patient support

    Research Partnership’s Emilie Braund and Harrison Gaiger dig down into the top insights pharma companies can harness to make their patient support programmes as powerful as possible. The pandemic has undoubtedly disrupted the healthcare landscape and amplified the complex factors that influence and shape patient journeys. Findings from our recently published whitepaper ‘Free thinking: The […]